2-47806653-T-C
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.4001+2T>C variant causes a splice donor, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000069 in 1,449,400 control chromosomes in the GnomAD database, with no homozygous occurrence. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★★).
Frequency
Consequence
NM_000179.3 splice_donor, intron
Scores
Clinical Significance
Conservation
Publications
- intellectual developmental disorder with dysmorphic facies and behavioral abnormalitiesInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000179.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH6 | NM_000179.3 | MANE Select | c.4001+2T>C | splice_donor intron | N/A | NP_000170.1 | |||
| MSH6 | NM_001406795.1 | c.4097+2T>C | splice_donor intron | N/A | NP_001393724.1 | ||||
| MSH6 | NM_001406813.1 | c.4007+2T>C | splice_donor intron | N/A | NP_001393742.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MSH6 | ENST00000234420.11 | TSL:1 MANE Select | c.4001+2T>C | splice_donor intron | N/A | ENSP00000234420.5 | |||
| MSH6 | ENST00000445503.5 | TSL:1 | n.*3348+2T>C | splice_donor intron | N/A | ENSP00000405294.1 | |||
| FBXO11 | ENST00000682451.1 | n.4095A>G | non_coding_transcript_exon | Exon 23 of 23 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.90e-7 AC: 1AN: 1449400Hom.: 0 Cov.: 34 AF XY: 0.00000139 AC XY: 1AN XY: 721442 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome Pathogenic:2
Variant causes splicing aberration, >2 MSI-H, co-segregation with disease & absent in 1000 genomes
PVS1_MOD; PP4_MOD; PM2_SUP; PP1
not provided Pathogenic:2
Lynch syndrome 5 Pathogenic:1
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This variant is not present in population databases (ExAC no frequency). This variant has been observed to segregate with disease in a Lynch syndrome family and has been observed in several individuals and families with suspected Lynch syndrome (PMID: 18566915, 21836479, 25648859, 22495361). ClinVar contains an entry for this variant (Variation ID: 89501). Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This sequence change affects a donor splice site in the last intron (intron 9) of the MSH6 gene. While this is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product.
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.4001+2T>C intronic pathogenic mutation results from a T to C substitution two nucleotides after coding exon 9 in the MSH6 gene. This alteration occurs at the 3' terminus of the MSH6 gene and is not expected to trigger nonsense-mediated mRNA decay. The exact functional effect of this alteration is unknown; however, the impacted region is critical for protein function (Ambry internal data). This mutation has been reported in several Danish HNPCC/Lynch syndrome families (Nilbert M et al. Fam. Cancer 2009;8(1):75-83; Jensen UB et al. Breast Cancer Res. Treat., 2010 Apr;120:777-82; Okkels H et al. Appl Immunohistochem Mol Morphol. 2012 Oct;20(5):470-7; Therkildsen C et al. Eur. J. Neurol., 2015 Apr;22:717-24). This variant has also been identified in probands whose HNPCC/Lynch syndrome-associated tumors demonstrated loss of MSH6 expression by immunohistochemistry (Ambry internal data). RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at